Recombinant Human MAPK13, N-His

Description of Recombinant Human MAPK13, N-His

Introduction

Recombinant Human MAPK13, N-His is a type of protein that plays a crucial role in various cellular processes, including cell growth, differentiation, and survival. This protein is a member of the mitogen-activated protein kinase (MAPK) family and is also known as p38delta. In this article, we will explore the structure, activity, and potential applications of this protein as a drug target.

Structure of Recombinant Human MAPK13, N-His

Recombinant Human MAPK13, N-His is a 417 amino acid protein with a molecular weight of approximately 48 kDa. It contains a N-terminal His-tag, which allows for easy purification and detection of the protein. The structure of this protein is similar to other members of the MAPK family, consisting of an N-terminal kinase domain, a linker region, and a C-terminal regulatory domain. The kinase domain is responsible for the catalytic activity of the protein, while the regulatory domain is involved in substrate recognition and binding.

Activity of this protein

Recombinant Human MAPK13, N-His is a serine/threonine kinase, meaning it catalyzes the transfer of phosphate groups to serine and threonine residues on target proteins. This activity is crucial for the regulation of various cellular processes, including cell growth, differentiation, and apoptosis. MAPK13 is activated by various stimuli, such as stress, cytokines, and growth factors, and is involved in both pro-inflammatory and anti-inflammatory signaling pathways.

One of the unique features of MAPK13 is its ability to phosphorylate specific substrates, such as the transcription factor ATF2, which is involved in the expression of genes related to cell survival and apoptosis. This specificity makes MAPK13 an attractive drug target for the treatment of diseases related to dysregulated cell growth and survival, such as cancer.

Application as a Drug Target

The dysregulation of MAPK13 activity has been linked to various diseases, including cancer, inflammatory disorders, and neurodegenerative diseases. Therefore, targeting MAPK13 with specific inhibitors has been explored as a potential therapeutic strategy.

In cancer, MAPK13 has been shown to play a role in cell proliferation, survival, and metastasis. Inhibiting MAPK13 activity has been found to reduce tumor growth and sensitize cancer cells to chemotherapeutic agents. This makes MAPK13 an attractive target for the development of anti-cancer drugs.

In inflammatory disorders, MAPK13 has been implicated in the production of pro-inflammatory cytokines, such as TNF-alpha and IL-6. Inhibiting MAPK13 activity has been shown to reduce inflammation in animal models of rheumatoid arthritis and inflammatory bowel disease. This suggests that MAPK13 inhibitors could be used as potential therapeutics for these conditions.

Furthermore, MAPK13 has been linked to the pathogenesis of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s. Inhibiting MAPK13 activity has been found to protect neurons from cell death and improve cognitive function in animal models of these diseases. This highlights the potential of MAPK13 inhibitors as neuroprotective agents.

Conclusion

In summary, Recombinant Human MAPK13, N-His is a protein with a crucial role in various cellular processes. Its structure and activity make it an attractive drug target for the treatment of diseases related to dysregulated cell growth and survival. Further research and development of MAPK13 inhibitors could lead to the development of novel therapeutics for cancer, inflammatory disorders, and neurodegenerative diseases.